SV2002000440A - Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb - Google Patents

Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb

Info

Publication number
SV2002000440A
SV2002000440A SV2001000440A SV2001000440A SV2002000440A SV 2002000440 A SV2002000440 A SV 2002000440A SV 2001000440 A SV2001000440 A SV 2001000440A SV 2001000440 A SV2001000440 A SV 2001000440A SV 2002000440 A SV2002000440 A SV 2002000440A
Authority
SV
El Salvador
Prior art keywords
disease
inhibitor
procedure
treatment
cognitive
Prior art date
Application number
SV2001000440A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Brian Thomas O'neill
Steven Bradley Sands
Eric Jacob Watsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000440A publication Critical patent/SV2002000440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE TRATAMIENTO DE ENFERMEDADES DE DISFUNSION COGNITIVA EN UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE UN AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; Y UN INHIBIDOR DE ACETILCOLINESTRA, UN INHIBIDOR DE BUTILCOLINESTERASA, UN AGENTE ENTROGENICO, UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTREOGENOS O UN AGONISTA MUSCARINICO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE. EL AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA Y EL INHIBIDOR DE ACETILCOLINESTERASA, EL INHIBIDOR DE BUTILCOLINESTERASA, EL ESTROGENO, EL MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS O EN ANTAGONISTA MUSCARINICO ESTAN PRESENTES EN CANTIDADES QUE HACEN A LA COMPOSICION EFICAZ EN LA POTENCIACION DE LA COGNICION O EN EL TRATAMIENTO DE ENFERMEDADES DE DISFUNCION COGNITIVA QUE INCLUYEN, PERO SIN LIMITACION, LA ENFERMEDAD DE ALZHEIMER, DETERIORO COGNITIVO LEVE, DISMINUCION COGNITIVA RELACIONADAD CON LA EDAD, DEMENCIA VASCULAR, DEMENCIA POR ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, APOPLEJIA, TBI, DEMENCIA ASOCIADA CON EL SIDA Y ESQUIZOFRENIA. TAMBIEN SE DESCRIBE EL PROCEDIMIENTO DE USO DE ESTAS COMPOSICIONES
SV2001000440A 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb SV2002000440A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
SV2002000440A true SV2002000440A (es) 2002-10-24

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000440A SV2002000440A (es) 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb

Country Status (17)

Country Link
US (2) US20010036949A1 (es)
EP (1) EP1280554A2 (es)
JP (1) JP2003532670A (es)
AR (1) AR028426A1 (es)
AU (1) AU2001248699A1 (es)
BR (1) BR0110487A (es)
CA (1) CA2409720A1 (es)
EC (1) ECSP014065A (es)
GT (1) GT200100075A (es)
MX (1) MXPA02011051A (es)
PA (1) PA8516701A1 (es)
PE (1) PE20011256A1 (es)
PY (1) PY0108909A (es)
SV (1) SV2002000440A (es)
TN (1) TNSN01068A1 (es)
UY (1) UY26693A1 (es)
WO (1) WO2001085145A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU2002234836B2 (en) * 2001-04-20 2007-08-23 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
IL160208A0 (en) * 2001-08-31 2004-07-25 Neurochem Int Ltd Amidine derivatives for treating amyloidosis
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
WO2005000806A2 (en) * 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
CN101921279A (zh) 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AU2005244867A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
JP2008500368A (ja) * 2004-05-27 2008-01-10 ミジェニックス コーポレイション 細胞保護のための２置換１７−イミノエストロゲン化合物
EP2258358A3 (en) * 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
WO2008033299A2 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
AR028426A1 (es) 2003-05-07
WO2001085145A3 (en) 2002-06-13
CA2409720A1 (en) 2001-11-15
TNSN01068A1 (fr) 2005-11-10
MXPA02011051A (es) 2003-03-10
US20030130303A1 (en) 2003-07-10
AU2001248699A1 (en) 2001-11-20
WO2001085145A8 (en) 2001-12-13
BR0110487A (pt) 2003-04-01
JP2003532670A (ja) 2003-11-05
EP1280554A2 (en) 2003-02-05
WO2001085145A2 (en) 2001-11-15
PE20011256A1 (es) 2001-12-29
ECSP014065A (es) 2003-01-13
US20010036949A1 (en) 2001-11-01
GT200100075A (es) 2001-12-31
PY0108909A (es) 2003-11-03
UY26693A1 (es) 2001-12-28
PA8516701A1 (es) 2002-09-17

Similar Documents

Publication Publication Date Title
SV2002000440A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb
CR7059A (es) USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BG66085B1 (bg) Фенилаланинови производни
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
PA8591701A1 (es) Derivados de pirrolopirimidina
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
BR0113980A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
TNSN01175A1 (fr) Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant.
SE0102055D0 (sv) New Compounds
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
SE0002729D0 (sv) Novel compound form
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
BG105434A (bg) Сертралинов орален концентрат
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
GEP20043377B (en) Pharmaceutical Complex
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
BR0005319A (pt) Tratamento combinado para depressão e ansiedade

Legal Events

Date Code Title Description
FC Refusal